BR0112918A - Composto, utilização do mesmo, processo de tratamento de distúrbios, processo para a preparação de composto, composição farmacêutica que compreende esse composto, processo para preparar uma composição e processo de tratamento de obesidade em um ser humano - Google Patents
Composto, utilização do mesmo, processo de tratamento de distúrbios, processo para a preparação de composto, composição farmacêutica que compreende esse composto, processo para preparar uma composição e processo de tratamento de obesidade em um ser humanoInfo
- Publication number
- BR0112918A BR0112918A BR0112918-0A BR0112918A BR0112918A BR 0112918 A BR0112918 A BR 0112918A BR 0112918 A BR0112918 A BR 0112918A BR 0112918 A BR0112918 A BR 0112918A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- composition
- treatment process
- preparing
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 201000010064 diabetes insipidus Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00116517 | 2000-07-31 | ||
| PCT/EP2001/008520 WO2002010169A1 (en) | 2000-07-31 | 2001-07-24 | Piperazine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0112918A true BR0112918A (pt) | 2003-07-01 |
Family
ID=8169405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0112918-0A BR0112918A (pt) | 2000-07-31 | 2001-07-24 | Composto, utilização do mesmo, processo de tratamento de distúrbios, processo para a preparação de composto, composição farmacêutica que compreende esse composto, processo para preparar uma composição e processo de tratamento de obesidade em um ser humano |
Country Status (20)
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1325008T3 (da) * | 2000-07-31 | 2006-02-13 | Hoffmann La Roche | Piperazinderivater |
| GB0106177D0 (en) | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| US7566728B2 (en) | 2002-03-29 | 2009-07-28 | Mitsubishi Tanabe Pharma Corporation | Remedy for sleep disturbance |
| NZ536664A (en) | 2002-06-19 | 2007-07-27 | Biovitrum Ab | Piperazinylpyrazine derivative compounds, their use and preparation |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| DE10320780A1 (de) * | 2003-05-09 | 2005-01-20 | Bayer Healthcare Ag | Heterocyclyl-substituierte Dihydrochinazoline |
| GB0314967D0 (en) * | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
| US20050032930A1 (en) * | 2003-07-02 | 2005-02-10 | Christian Jackson | Inkjet ink |
| WO2005028438A1 (ja) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
| DE10352499A1 (de) * | 2003-11-11 | 2005-06-09 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline II |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| DE102004022672A1 (de) * | 2004-05-07 | 2005-11-24 | Bayer Healthcare Ag | Substituierte Azachinazoline |
| WO2006022420A1 (ja) | 2004-08-25 | 2006-03-02 | Takeda Pharmaceutical Company Limited | 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法 |
| DK1814590T4 (da) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals Llc | Behandling af obesitet og beslægtede sygdomme. |
| AU2005333165B2 (en) | 2004-11-12 | 2012-07-19 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| US20090286723A1 (en) | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
| US7790712B2 (en) | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
| EP1888585B1 (en) * | 2005-05-03 | 2011-06-29 | F. Hoffmann-La Roche AG | Tetracyclic azapyrazinoindolines as 5-ht2 ligands |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| WO2006129826A1 (ja) | 2005-05-30 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
| DE102005027517A1 (de) * | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Verfahren zur Herstellung von Dihydrochinazolinen |
| EP1916239A4 (en) | 2005-08-10 | 2009-10-21 | Banyu Pharma Co Ltd | PYRIDOLVERBINDUNG |
| BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
| EP1921065B1 (en) | 2005-08-24 | 2010-10-20 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
| EP1939194A4 (en) | 2005-09-07 | 2010-12-08 | Banyu Pharma Co Ltd | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE |
| AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| US7569605B2 (en) * | 2005-10-14 | 2009-08-04 | Forest Laboratories Holdings Limited | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
| KR20080059233A (ko) | 2005-10-21 | 2008-06-26 | 노파르티스 아게 | 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물 |
| WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
| ES2381205T3 (es) | 2005-11-10 | 2012-05-24 | Msd K.K. | Derivado espiro aza-sustituido |
| AU2006324089A1 (en) | 2005-12-09 | 2007-06-14 | F. Hoffmann-La Roche Ag | Tricyclic amide derivatives useful for treating obesity |
| UA95788C2 (en) | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
| WO2007132841A1 (ja) | 2006-05-16 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物およびその用途 |
| CA2770486C (en) | 2006-09-22 | 2014-07-15 | Merck Sharp & Dohme Corp. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
| WO2008038692A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| MY154869A (en) | 2007-01-16 | 2015-08-14 | Ipintl Llc | Composition for treating metabolic syndrome |
| FR2912145B1 (fr) * | 2007-02-02 | 2009-03-06 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| MX2009011211A (es) | 2007-04-16 | 2009-10-30 | Abbott Lab | Indoles sustituidos en la posicion 7 inhibidores de mci-1. |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
| AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
| WO2009118411A2 (en) * | 2008-03-28 | 2009-10-01 | Nerviano Medical Sciences S.R.L. | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US20110015198A1 (en) | 2008-03-28 | 2011-01-20 | Banyu Pharmaceutical Co., Inc. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| CN102014847B (zh) * | 2008-04-28 | 2013-12-04 | 可乐丽则武齿科株式会社 | 牙科用组合物及复合树脂 |
| CA2666036C (en) | 2008-05-16 | 2017-09-12 | Chien-Hung Chen | Novel compositions and methods for treating hyperproliferative diseases |
| CA2930674A1 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2301936A1 (en) | 2008-06-19 | 2011-03-30 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
| JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| WO2010013595A1 (ja) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | ５員－５員又は５員－６員縮環シクロアルキルアミン誘導体 |
| AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| EP2350010B1 (en) | 2008-10-30 | 2014-03-26 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
| FI122466B (fi) * | 2009-08-21 | 2012-01-31 | Hollming Oy | Menetelmä työstettävän metallikappaleen kuumentamiseksi ja induktiokuumennustyökalu |
| WO2011071136A1 (ja) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| BR122021002201A8 (pt) | 2011-02-25 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença |
| KR102034748B1 (ko) | 2011-03-01 | 2019-10-21 | 시너지 파마슈티컬즈 인코포레이티드 | 구아닐레이트 사이클라제 c 작용제의 제조 방법 |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| SMT201700009T1 (it) | 2012-03-16 | 2017-03-08 | Vitae Pharmaceuticals Inc | Modulatori del recettore x del fegato |
| MX354818B (es) | 2012-03-16 | 2018-03-21 | Vitae Pharmaceuticals Inc | Moduladores del receptor x del higado. |
| TWI579274B (zh) * | 2012-04-20 | 2017-04-21 | 龍馬躍公司 | 製備１－芳基－５－烷基吡唑化合物的改良方法 |
| AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| US9963453B2 (en) | 2013-04-23 | 2018-05-08 | Laboratorios Del Dr. Esteve S.A. | Substituted pyrazino[1,2-a]indoles as sigma receptor activity modulators |
| US9879015B2 (en) | 2013-04-23 | 2018-01-30 | Laboratorios Del Dr. Esteve S.A. | Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments |
| EP4424697A3 (en) | 2013-06-05 | 2024-12-25 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| USRE50634E1 (en) | 2014-01-24 | 2025-10-14 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| CA2959208C (en) | 2014-08-29 | 2023-09-19 | Tes Pharma S.R.L. | Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase |
| UA125334C2 (uk) | 2015-06-17 | 2022-02-23 | Пфайзер Інк. | Трициклічні сполуки та їх застосування як інгібіторів фосфодіестерази |
| RU2732405C2 (ru) | 2015-07-02 | 2020-09-16 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ |
| LT3319969T (lt) | 2015-07-06 | 2024-06-10 | Turning Point Therapeutics, Inc. | Diarilo makrociklo polimorfas |
| AU2017342083A1 (en) | 2016-10-14 | 2019-04-11 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE |
| JP7638868B2 (ja) | 2018-11-20 | 2025-03-04 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α－アミノ－β－カルボキシムコン酸セミアルデヒドデカルボキシラーゼ阻害剤 |
| EP3923933A4 (en) | 2019-02-13 | 2022-08-17 | Merck Sharp & Dohme Corp. | PYRROLIDINOREXINE RECEPTOR AGONISTS |
| TW202045476A (zh) | 2019-02-13 | 2020-12-16 | 美商默沙東藥廠 | 5-烷基吡咯啶食慾素受體促效劑 |
| WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| AU2021329805B2 (en) | 2020-08-18 | 2024-02-29 | Merck Sharp & Dohme Llc | Bicycloheptane pyrrolidine orexin receptor agonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US652018A (en) * | 1900-02-15 | 1900-06-19 | John C Duner | Gate. |
| US3317524A (en) | 1965-02-04 | 1967-05-02 | American Home Prod | Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles |
| DE2162422A1 (de) | 1971-12-16 | 1973-06-20 | Merck Patent Gmbh | Pyrazinoindol-derivate und verfahren zu ihrer herstellung |
| EP0572863A1 (de) * | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
| US5622950A (en) * | 1993-03-01 | 1997-04-22 | Merck, Sharp & Dohme Ltd. | Pyrrolo-pyridine derivatives |
| NZ261593A (en) | 1993-03-01 | 1996-09-25 | Merck Sharp & Dohme | 3-piperazinylmethly-1h-indolopyridine derivatives and pharmaceutical compositions |
| US5576319A (en) * | 1993-03-01 | 1996-11-19 | Merck, Sharp & Dohme Ltd. | Pyrrolo-pyridine derivatives |
| US6169086B1 (en) | 1997-01-27 | 2001-01-02 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole derivatives |
| JP2000169475A (ja) | 1998-07-24 | 2000-06-20 | Dai Ichi Seiyaku Co Ltd | ピラゾ―ル誘導体およびその塩 |
| AU3123400A (en) * | 1998-12-17 | 2000-07-03 | Wyeth | 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one derivates being 5ht2c agonists |
| GB9902047D0 (en) * | 1999-01-29 | 1999-03-17 | Cerebrus Ltd | Chemical compounds XI |
| DK1325008T3 (da) * | 2000-07-31 | 2006-02-13 | Hoffmann La Roche | Piperazinderivater |
-
2001
- 2001-07-24 DK DK01962869T patent/DK1325008T3/da active
- 2001-07-24 AU AU2001283955A patent/AU2001283955B2/en not_active Ceased
- 2001-07-24 JP JP2002515898A patent/JP4180365B2/ja not_active Expired - Fee Related
- 2001-07-24 DE DE60113865T patent/DE60113865T2/de not_active Expired - Fee Related
- 2001-07-24 CA CA002417106A patent/CA2417106C/en not_active Expired - Fee Related
- 2001-07-24 AU AU8395501A patent/AU8395501A/xx active Pending
- 2001-07-24 EP EP01962869A patent/EP1325008B1/en not_active Expired - Lifetime
- 2001-07-24 MX MXPA03000906A patent/MXPA03000906A/es active IP Right Grant
- 2001-07-24 BR BR0112918-0A patent/BR0112918A/pt not_active IP Right Cessation
- 2001-07-24 CN CNB018152260A patent/CN1277828C/zh not_active Expired - Fee Related
- 2001-07-24 ES ES01962869T patent/ES2250459T3/es not_active Expired - Lifetime
- 2001-07-24 KR KR10-2003-7001439A patent/KR100539139B1/ko not_active Expired - Fee Related
- 2001-07-24 WO PCT/EP2001/008520 patent/WO2002010169A1/en not_active Ceased
- 2001-07-24 AT AT01962869T patent/ATE305933T1/de not_active IP Right Cessation
- 2001-07-25 PE PE2001000749A patent/PE20020366A1/es not_active Application Discontinuation
- 2001-07-25 US US09/912,949 patent/US20020035110A1/en not_active Abandoned
- 2001-07-27 AR ARP010103589A patent/AR030306A1/es unknown
- 2001-07-30 GT GT200100155A patent/GT200100155A/es unknown
- 2001-07-30 UY UY26863A patent/UY26863A1/es not_active Application Discontinuation
- 2001-07-30 PA PA20018523601A patent/PA8523601A1/es unknown
-
2003
- 2003-01-20 ZA ZA200300525A patent/ZA200300525B/en unknown
- 2003-03-25 US US10/396,242 patent/US6933387B2/en not_active Expired - Fee Related
-
2005
- 2005-06-28 US US11/169,079 patent/US7253281B2/en not_active Expired - Fee Related
-
2007
- 2007-01-03 US US11/649,132 patent/US20070106076A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2250459T3 (es) | 2006-04-16 |
| AU2001283955B2 (en) | 2006-05-18 |
| US20030216401A1 (en) | 2003-11-20 |
| ZA200300525B (en) | 2004-04-20 |
| JP2004505085A (ja) | 2004-02-19 |
| UY26863A1 (es) | 2002-01-31 |
| PE20020366A1 (es) | 2002-05-17 |
| PA8523601A1 (es) | 2002-10-24 |
| CN1452622A (zh) | 2003-10-29 |
| AU8395501A (en) | 2002-02-13 |
| US20070106076A1 (en) | 2007-05-10 |
| DE60113865T2 (de) | 2006-07-20 |
| MXPA03000906A (es) | 2005-02-24 |
| ATE305933T1 (de) | 2005-10-15 |
| GT200100155A (es) | 2002-05-16 |
| JP4180365B2 (ja) | 2008-11-12 |
| AR030306A1 (es) | 2003-08-20 |
| CN1277828C (zh) | 2006-10-04 |
| US20020035110A1 (en) | 2002-03-21 |
| EP1325008B1 (en) | 2005-10-05 |
| DK1325008T3 (da) | 2006-02-13 |
| US20050239789A1 (en) | 2005-10-27 |
| US7253281B2 (en) | 2007-08-07 |
| EP1325008A1 (en) | 2003-07-09 |
| KR20030020954A (ko) | 2003-03-10 |
| DE60113865D1 (de) | 2006-02-16 |
| CA2417106C (en) | 2007-09-18 |
| CA2417106A1 (en) | 2002-02-07 |
| KR100539139B1 (ko) | 2005-12-26 |
| WO2002010169A1 (en) | 2002-02-07 |
| US6933387B2 (en) | 2005-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0112918A (pt) | Composto, utilização do mesmo, processo de tratamento de distúrbios, processo para a preparação de composto, composição farmacêutica que compreende esse composto, processo para preparar uma composição e processo de tratamento de obesidade em um ser humano | |
| BR0116605A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono | |
| BR0116201A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende o composto, utilização do composto, processo para o tratamento e profilaxia de distúrbios e para o tratamento de obesidade | |
| BR0208111A (pt) | Composto, utilização de um composto, processo de tratamento de distúrbios, processo para preparação de composto, composição farmacêutica que compreende o composto e processo de tratamento de obesidade | |
| BR0009486A (pt) | Compostos que contêm uma amida, utilização desses compostos, composição farmacêutica, processo para o tratamento profilático ou terapêutico de, diabetes do tipo ii e processo para a preparação dos compostos | |
| BR0107532A (pt) | Composto, uso do composto, método para o tratamento de disfunções neurológicas associadas com a produção de b-amilóide, método de inibição da atividade de y-secretase e composição farmacêutica | |
| BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| BR0205391A (pt) | Hidrato a de aripiprazol, processo para a preparação do hidrato a, substância de medicamento de aripiprazol de hogroscopicidade baixa, cristais de anidro de aripiprazol b, processos para a preparação de cristais de anidrido de aripiprazol b e para a preparação de uma preparação oral sólida farmacêutica, uso de cristais de anidrido de aripiprazol b, medicamento para tratar a esquizofrenia ou os sintomas associados com a esquizofrenia, processo para preparação de grânulos, preparação oral sólida farmacêutica, cristais de anidrido de aripiprazol c até g, processo para a preparação de cristais de anidridro de aripiprazol c até g, e, composição farmacêutica. | |
| EA201590835A1 (ru) | Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием | |
| BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
| BRPI0512220A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
| EA201070121A1 (ru) | Лекарственная форма, содержащая слитый белок glp-1-fc | |
| TR200100377T2 (tr) | Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar. | |
| BRPI0411484A (pt) | composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica | |
| BR0008979A (pt) | Composto quìmico, uso de um composto, método de tratamento, processo de preparação de um composto, composição farmacêutica e método de fabricação da mesma | |
| BR0214986A (pt) | S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
| CL2003002683A1 (es) | Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos, | |
| SE0104340D0 (sv) | New compounds | |
| BR0110051A (pt) | Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer | |
| DE69400435D1 (de) | Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen | |
| BR0307441A (pt) | Compostos, processo para a preparação de um composto, composição farmacêutica, utilização desses compostos, método para o tratamento e profilaxia de enfermidades e método para o tratamento de obesidade | |
| BRPI0408882A (pt) | composições contendo lactulose para tratamento de infecções por rotavìrus | |
| BRPI0415953A (pt) | formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação | |
| BRPI0512335A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização | |
| BR0115045A (pt) | Compostos, processo para sua preparação, composição farmacêutica que compreende os mesmos, sua utilização, processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7O E 8O ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2021 DE 29/09/2009. |